Spectrum Pharmaceuticals - Chancen und Risiken? (Seite 113)

[Ville7]

Antwort auf Beitrag Nr.: 42.076.384 von Ville7 am 12.09.11 18:07:16

Nach dem angekündigten Aktienrückkauf könnte 6,x wiederum unrealistisch sein. Man weiß nicht, zu welchen Kursen Raj zuschlägt...

[Ville7]

Antwort auf Beitrag Nr.: 42.058.988 von VaJo am 08.09.11 10:57:06

Trend zeigt weiter mit dem Markt nach unten. Mal sehen wo der Boden ist. Ich schätze bei 6,x.

[VaJo]

SPPI hat den Sturm bisher sehr gut überstanden. Ich hoffe mal es geht jetzt im Trend weiter...

[Tommi33]

http://seekingalpha.com/article/286083-spectrum-pharmaceutic…

LG Tommi

[Ville7]

Antwort auf Beitrag Nr.: 41.900.689 von Magnetfeldfredy am 05.08.11 14:15:05

Was sehr hoch fliegt kommt meist weit zurück. Siehe Elan, Genmab, Intercell, Dendreon, ... es gibt da zig Biotechbeispiele der letzten Jahre...

[Ville7]

Antwort auf Beitrag Nr.: 41.891.177 von VaJo am 04.08.11 12:54:47

Ich war enttäuscht. Nachdem Raj bereits 10Tage vor Quartalsende ein Rekordquartal für Q2 ankündigte wurden Hoffnungen geweckt, dass die Umsätze deutlich über Q1 sind. Sie waren aber nur marginal darüber.

Zumindest hat Raj scheints für Q3 ähnliche Umsätze wie in Q2 angedeutet. Das wäre sehr gut für die Stabilisierung des Kurses...

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 41.900.668 von Ville7 am 05.08.11 14:12:39

Ja, so ist`s im Leben!

[Ville7]

Zitat von Ville7: Kurse um 10 Euro gibt der Chart aktuell m.E. nicht her. Die erwarteten Q2-Zahlen geben m.E. nicht mehr genug Schub für höhere Kurse. 10 Euro könnte allerallerfrühestens in Q3/Q4 der Fall sein. Hoffen wir, dass die Shortage Spectrum weiterhin gigantische Umsätze beschert.

Einschätzung war richtig. Hoffen wir, dass der Gesamtmarkt nicht voll wegkackt, dann kann dass ab Q4/2011 bis Q3 2012 mit 10Euro klappen.

[Ville7]

Zitat von Magnetfeldfredy: Ich hätte nichts gegen eine zweite Dendreon, bin mit dabei!

Bitte nicht.

[Oberlaendler]

Spectrum Pharmaceuticals Generates Cash from Operations, Reports Third Consecutive Profitable Quarter, and Record Revenue for the Three- and Six-Month Periods Ended June 30, 2011; Strongest Financial Position in Company History

Outstanding Financial Results Include Three- and Six-Month Total Revenues of $45.4 Million and $89.0 Million, Respectively, Vs. $12.3 Million and $23.4 Million in 2010
Over 350% and 400% Increase, Respectively, in Three- and Six-Month 2011 Product Sales Vs. Three- and Six-Month 2010 Product Sales
$165 Million In Cash, Cash Equivalents, Investments and Receivables as of June 30, 2011, an Increase from $141 Million as of March 31, 2011
FUSILEV® Received FDA Approval for Advanced Metastatic Colorectal Cancer on April 29, 2011
Two New Drug Application Filings (Apaziquone and Belinostat) on Track for 2012
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today reported its strongest financial position ever as of June 30, 2011.

“We are extremely pleased with our third consecutive profitable quarter, strong cash flow, and record revenues,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “The robust sales of FUSILEV and ZEVALIN in the second quarter demonstrate the significant and sustained recognition by physicians of the therapeutic value of these products. The FDA approval of FUSILEV on April 29th was a highly transformational event for Spectrum Pharmaceuticals. We are now able to promote FUSILEV and meet the pressing needs of tens of thousands of colorectal cancer patients. As you may know, during the second quarter, we were unable to fully meet the demand for FUSILEV, until we secured FDA approval of additional supply sources. As we announced on June 21st, Spectrum now has ample supplies of FUSILEV to meet patient needs. Regarding ZEVALIN, which we believe is the most effective single-agent for the treatment of follicular non-Hodgkin’s lymphoma, we continue to work with the FDA regarding the removal of the bioscan requirement. Looking forward, we are currently on track to file two New Drug Applications in 2012 for apaziquone and belinostat. We believe these two novel drugs have great potential in the treatment of bladder cancer and Peripheral T-Cell Lymphoma, respectively.”

Three-Month Period Ended June 30, 2011 (All #s are Approximate)

The Company recorded net income of $7.2 million, or $0.14 per basic and $0.12 per diluted share, compared to a net loss of $9.7 million, or ($0.20) per basic and diluted share, in the second quarter of 2010. Consolidated revenue of $45.4 million was comprised of product sales of $42.3 Million ($33.9 million from FUSILEV, $8.4 million from ZEVALIN) and $3.1 million from licensing fees. This represents a 268% increase from the $12.3 million in consolidated revenue recorded in the second quarter of 2010, comprised of product sales of $9.3 million ($2.4 million from FUSILEV, $6.9 million from ZEVALIN) and $3.1 million from licensing fees. Total research and development expenses were $7.7 million, as compared to $6.3 million in the same period of 2010. Selling, general and administrative expenses were $18.7 million, which includes non-cash charges of $6.8 million, as compared to $13.8 million in the same period in 2010, which includes non-cash charges of $1.7 million.

Six-Month Period Ended June 30, 2011 (All #s are Approximate)

The Company recorded net income of $20.0 million, or $0.39 per basic and $0.35 per diluted share, compared to a net loss of $48.7 million, or ($1.00) per basic and diluted share, in the six-month period ended June 30, 2010. Consolidated revenue of $89.0 million was comprised of product sales of $82.8 million ($68.6 million from FUSILEV, $14.3 million from ZEVALIN) and $6.2 million from licensing fees. This represents a 280% increase from $23.4 million in consolidated revenue recorded in the first six months of 2010, comprised of product sales of $16.4 million ($3.0 million from FUSILEV, $13.4 million from ZEVALIN) and $7.0 million from licensing fees. Total research and development expenses were $13.5 million, as compared to $42.8 million in the same period of 2010. Selling, general and administrative expenses were $31.5 million, compared to $24.7 million in the same period in 2010.

During the six-month period ended June 30, 2011, net cash provided by operations was approximately $12.3 million. Cash, cash equivalents, investments and receivables as of June 30, 2011 aggregated $165 million, as compared to $141 million as of March 31, 2011, and $125 million as of December 31, 2010.

There are approximately 53 million shares of common stock issued and outstanding as of June 30, 2011.

Conference Call

Thursday, August 4, 2011 @ 1:30 p.m. Eastern/10:30 a.m. Pacific

Domestic: [phone], Conference ID# 81692490

International: [phone], Conference ID# 81692490

On the conference call, management will review the financial results, provide an update on the Company’s business and discuss expectations for the future.

Webcast and replays: www.sppirx.com

Conference Call audio replays will be available through August 18, 2011

Domestic: 800-642-1687
International: 706-645-9291


2011/2012 Expected Corporate Events and Potential Valuation Catalysts

FUSILEV®

Continue to promote FUSILEV in advanced metastatic colorectal cancer and continue to grow revenue
Initiate additional clinical studies to expand FUSILEV indications
ZEVALIN®

Initiate studies in 2011, including in Diffuse Large B-Cell Lymphoma
Bioscan removal FDA decision date (PDUFA) – November 20, 2011
Belinostat

Completing enrollment in 2011
File NDA in 2012
Apaziquone

File NDA in 2012
About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company’s strategy is to acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates. The Company has assembled an integrated in-house scientific team, including clinical development, medical research, regulatory affairs, biostatistics and data management, formulation development, and has established a commercial infrastructure for the marketing of its drug products. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company’s website at www.sppirx.com.

Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed,” and similar expressions are intended to identify forward-looking statements.These statements are based on management’s current beliefs and expectations.These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees, around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission.Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this press release.We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC. ®, ZEVALIN®, and FUSILEV® are registered trademarks of Spectrum Pharmaceuticals, Inc.REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc.

© 2011 Spectrum Pharmaceuticals, Inc. All Rights Reserved

SPECTRUM PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)

(unaudited)


Three Months Ended

June 30,
Six Months Ended

June 30,

2011 2010 2011 2010
Revenues:
Product sales, net $ 42,287 $ 9,268 $ 82,810 $ 16,390
License and contract revenue 3,075 3,075 6,150 7,042
Total revenues $ 45,362 $ 12,343 $ 88,960 $ 23,432

Operating costs and expenses:
Cost of product sales (excludes amortization of purchased intangible assets) 8,130 3,592 14,710 6,837
Selling, general and administrative 18,699 13,802 31,450 24,664
Research and development 7,686 6,285 13,516 42,829
Amortization of purchased intangibles 930 930 1,860 1,860
Total operating costs and expenses 35,445 24,609 61,536 76,190

Income (loss) from operations 9,917 (12,266 ) 27,424 (52,758 )
Change in fair value of common stock warrant liability (1,237 ) 2,826 (6,487 ) 4,401
Other income, net 174 (236 ) 694 (333 )

Income (loss) before provision for income taxes 8,854 (9,676 ) 21,631 (48,690 )
Provision for income taxes (1,650 ) — (1, 650 ) —

Net income (loss) $ 7,204 $ (9,676 ) $ 19,981 $ (48,690 )

Net income (loss) per share:
Basic $ 0.14 $ (0.20 ) $ 0.39 $ (1.00 )
Diluted $ 0.12 $ (0.20 ) $ 0.35 $ (1.00 )

Weighted average shares outstanding:
Basic 52,257,049 49,020,236 51,814,122 48,844,918
Diluted 58,265,264 49,020,236 56,845,371 48,844,918

SUMMARY CONSOLIDATED BALANCE SHEETS
(In thousands)
(unaudited)

June 30,

2011
December 31,

2010


Cash, cash equivalents and marketable securities 104,437 95,674
Accounts receivable, net 46,471 21,051
Inventories, net 9,399 4,234
Prepaid expenses and other current assets 883 906
Total current assets 161,190 121,865
Investments 14,095 8,569
Property and equipment, net 3,050 3,158
Intangible assets, net 43,962 29,605
Other assets 379 434

Total Assets $ 222,676 $ 163,631

Current liabilities $ 89,209 $ 63,322
Deferred revenue and other credits – less current portion 19,290 25,495
Other long-term liabilities 323 338
Total liabilities 108,822 89,155
Total stockholders’ equity 113,854 74,476
Total liabilities and stockholders’ equity $ 222,676 $ 163,631


Non-GAAP Financial Measures

The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with generally accepted accounting principles (GAAP). The non-GAAP financial measures presented exclude the items summarized in the below table. Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results and that these items are not indicative of the Company’s on-going core operating performance.

Management uses non-GAAP net income (loss) in its evaluation of the Company’s core after-tax results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Management believes that providing these non-GAAP financial measures allows investors to view the Company’s financial results in the way that management views the financial results.

The non-GAAP financial measures presented herein have certain limitations in that they do not reflect all of the costs associated with the operations of the Company’s business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.

NON-GAAP INCOME (LOSS) RECONCILIATION
(In thousands)


Three Months Ended Six Months Ended
June 30, June 30,
(unaudited) (unaudited)
2011 2010 2011 2010
GAAP income (loss) before income taxes $ 8,854 $ (9,676 ) $ 21,631 $ (48,690 )
Stock-based compensation 6,816 1,737 10,880 4,212
Change in fair value of common stock warrant liability 1,237 (2,826 ) 6,487 (4,401 )
Income (loss) before income taxes 16,907 (10,765 ) 38,998 (48,879 )
Estimated provision for income taxes (3,200 ) -- (3,200 ) --
Non-GAAP income (loss) $ 13,707 $ (10,765 ) $ 35,798 $ (48,879 )

Non-GAAP income (loss) per share-basic $ 0.26 $ (0.22 ) $ 0.69 $ (1.00 )

Source: Spectrum Pharmaceuticals, Inc.

Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

MMn hat SPPI mit Fusilev und der Knappheit Glück gehabt, Zevalin scheint bis jetzt nicht der Bringer zu sein. Aber letzten Endes ist es egal, woher die Gewinne kommen und vielleicht zündet Zevalin nach der Entfernung des Bioscans ja noch. Nächstes Jahr wird noch mal spannend mit Belinostat und Apaziquone.

Grüße Oberländler